CompletedPhase 2NCT00324779
Rituximab in Treating Young Patients Who Are Receiving Chemotherapy for B-Cell Non-Hodgkin's Lymphoma or B-Cell Acute Lymphoblastic Leukemia
Studying Burkitt lymphoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- University Hospital Erlangen
- Principal Investigator
- Alfred Reiter, MDUniversity Hospital Erlangen
- Intervention
- rituximab(biological)
- Enrollment
- 79 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2004
Study locations (30)
- Kinderklinik - Universitaetsklinikum Aachen, Aachen, Germany
- Klinikum Augsburg, Augsburg, Germany
- Charite - Campus Charite Mitte, Berlin, Germany
- Helios Klinikum Berlin, Berlin, Germany
- Evangelisches Krankenhauus Bielfeld, Biefeld, Germany
- Klinikum Bremen-Mitte, Bremen, Germany
- Children's Hospital, Cologne, Germany
- Vestische Kinderklinik, Datteln, Germany
- Universitatsklinikum Carl Gustav Carus, Dresden, Germany
- Helios Klinikum Erfurt, Erfurt, Germany
- Universitaets - Kinderklinik, Erlangen, Germany
- Universitaetsklinikum Essen, Essen, Germany
- Klinikum der J.W. Goethe Universitaet, Frankfurt, Germany
- Universitaetskinderklinik - Universitaetsklinikum Freiburg, Freiburg im Breisgau, Germany
- Kinderklinik, Giessen, Germany
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00324779 on ClinicalTrials.govOther trials for Burkitt lymphoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1, PHASE2NCT07069699Testing the Safety of Anti-Cancer Drug, CX-5461 (Pidnarulex), in Treating Lymphoma With Specific Changes in the MYC GeneNational Cancer Institute (NCI)
- RECRUITINGEARLY PHASE1NCT07429461Clinical Study of SYNCAR-100 in the Treatment of Relapsed/Refractory Acute B-Lymphoblastic LeukemiaZhejiang University
- RECRUITINGEARLY PHASE1NCT06793241Donor Derived CD19 CAR-T Cells in the Treatment of R/R B-cell Acute Lymphoblastic LeukemiaZhejiang University
- RECRUITINGPHASE2, PHASE3NCT06764238Newly-diagnosed Intermediate/High Risk Pediatric B-cell ALL ProtocolInstitute of Hematology & Blood Diseases Hospital, China
- RECRUITINGNCT06796517Immunotherapy in LymphomaSung-Soo Park
- RECRUITINGPHASE1NCT06060782Thiotepa, Cyclophosphamide, Clarithromycin and CytarabineFifth Affiliated Hospital, Sun Yat-Sen University
- RECRUITINGPHASE2NCT06179524CAR-T-19 Injection in the Treatment of CD19-positive Relapsed/Refractory B-ALLBeijing Yongtai Ruike Biotechnology Company Ltd
- RECRUITINGPHASE1NCT06056752QH103 Cell Injection for the Treatment of Relapsed/Refractory B-cell Acute Lymphoblastic LeukemiaAnhui Provincial Hospital